Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | TGFBR1 | P36897 | 8/20 | 0.51 |
| ▸ | STS | P08842 | 2/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5341195 | 0.88 | MC4R (0.51) | MEN1KMT2ASTSACHE | |
| SCHEMBL5332747 | 0.87 | MEN1 (0.48) | MEN1KMT2ATGFBR1STSACHE | |
| SCHEMBL5335815 | 0.85 | MEN1 (0.47) | MEN1KMT2ATGFBR1STSACHE | |
| SCHEMBL5336824 | 0.83 | MEN1 (0.46) | MEN1KMT2ATGFBR1STSACHE | |
| SCHEMBL416461 | 0.83 | ACHE (0.51) | MEN1KMT2AACHELMNA | |
| SCHEMBL29115135 | 0.82 | GAA (0.58) | MEN1KMT2ATGFBR1LMNA | |
| SCHEMBL5343865 | 0.81 | ACHE (0.46) | MEN1KMT2ASTSACHE | |
| SCHEMBL5336255 | 0.81 | MCOLN3 (0.62) | MEN1KMT2ATGFBR1STS | |
| SCHEMBL7981893 | 0.81 | GAA (0.56) | ACHELMNA | |
| SCHEMBL5338122 | 0.81 | ACHE (0.49) | MEN1KMT2AACHELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291619-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291619-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1368340-B1 | PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | LILLY CO ELI (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20040092507-A1 | Melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092507-A1 | Melanocortin receptor agonists | MC1R, MC4R, MC5R | MEN1 683/4885KMT2A 2707/4885TGFBR1 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.